Navigation and service

You are here:Rote-Hand-Briefe and Information Letters

Dear Doctor Letter for contraceptives containing dienogest and ethinylestradiol: Risk of venous thromboembolism

Date 2018.12.11
Active substance dienogest, ethinylestradiol

The company Jenapharm GmbH & Co. KG provides information on the risk of venous thromboembolism (VTE) in women using contraceptives containing dienogest and ethinylestradiol compared to women using levonorgestrel and ethinylestradiol combinations, which are associated with a lower risk.